A £90 Million Lawsuit against Reckitt Benckiser

.

A £90 Million Lawsuit against Reckitt Benckiser

While preparing to sue the manufacturers of the heartburn remedy Gaviscon for almost £90 million, NHS has made serious allegations against Reckitt Benckiser saying that the firm had charged doctors with a more expensive version of the medicine when there existed a lesser expensive one.

Recently, in another case, the Office of Fair Trading had fined it £10.2 million after the officials from Reckitt Benckiser admitted breaking UK and EU legislation with the sale of the medicine to the health service.

Reckitt Benckiser's Gaviscon Original was quite a popular medicine and it was very frequently prescribed by the doctors. As its patent had to expire in 2005, other companies got a chance to offer something at a cheaper rate.

But rather than putting forward a generic name allowing cheaper versions to enter into the market, the company left doctors with no option after proposing Gaviscon Advance.

But the whole plan was exposed when an anonymous source revealed, “Reckitt cheated the Health Service. It could have saved the NHS millions of pounds. I felt it had to be exposed”.

Admitting to fail to allow competition, the company said that it had not cheated NHS in any case and it was not happy about the inappropriate language used in the internal correspondence.


Latest News

Report Shows Large Number of Americans still Prefer Receiving Credit Card Statem
U.S. Big Banks Pass Annual Stress Test
Viacom’s Board will Remain as it is for the Time being, Judge Sets Hearing for J
Crude Stockpiles Drop in the U. S
A New Study Highlights that U. S. Expected to Spend $2.6 Trillion Less than Esti
SolarCity Shares Soar with Tesla's Bid for the Company
The Leave as well as Remain Camps Gathers Pace in Brexit
Oil’s Advance Halts as Market Awaits U.S Stock Pile Data and Brexit Poll
Martin Winterkorn and a Current VW Board Member Under Investigation by Prosecuto
Survey Shows Some Workplace Benefits are Fading with Time
Kimco Realty Corporation Shares Climbed 0.21 Percent Last Week
Sluggish Growth and Inflation is Taking More Time Than Expected Affecting Fed’s